<DOC>
	<DOCNO>NCT00202384</DOCNO>
	<brief_summary>Clinical experimental evidence suggest variability therapeutic response immunomodulating therapy Multiple Sclerosis patient . Microarrays technology permit monitor expression level thousand gene time . The specific aim study identify predictive factor therapeutic response MS patient treat high-dose Interferon-Beta .</brief_summary>
	<brief_title>Gene Expression MS Patients Before During Treatment With Interferon-beta</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<criteria>diagnosis relapsingremitting MS ( McDonald criterion ) age 1855 EDSS le equal 5.5 use disease modify drug use corticosteroid 3 month start protocol clinical relapse 1 month start protocol serious heart , renal , hepatic haematological dysfunction define laboratory exam</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>microarrays</keyword>
</DOC>